Premium
Long‐acting injectable paliperidone shows greater benefit in early‐stage schizophrenia
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30717
Subject(s) - paliperidone , schizophrenia (object oriented programming) , medicine , paliperidone palmitate , stage (stratigraphy) , duration (music) , psychiatry , antipsychotic , art , literature , paleontology , biology
Patients with schizophrenia who received monthly doses of long‐acting injectable (LAI) paliperidone in a 25‐week study showed improvement in both clinical and functional outcomes, with the greatest improvement seen among the group of patients with a shorter duration of illness. The findings based on duration of illness are noteworthy in that most treatment with LAI antipsychotics has targeted patients with a longer illness history.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom